Skip Navigation


JAC Advance Access originally published online on May 13, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/6/1437    most recent
dkg263v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Credito, K. L.
Right arrow Articles by Appelbaum, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Credito, K. L.
Right arrow Articles by Appelbaum, P. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 1437-1439
© 2003 The British Society for Antimicrobial Chemotherapy

Correspondence

In vitro activity of faropenem compared with eight agents against fourteen Gram-positive and Gram-negative bacteria by time–kill

Kim L. Credito1, Michael R. Jacobs2 and Peter C. Appelbaum1,*

1 Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033; 2 Case Western Reserve University, Cleveland, OH 44106, USA

Keywords: faropenem, cidality

The first 10% of the full text of this article appears below.

Sir,

Faropenem is a novel oral ß-lactam antimicrobial (no longer under development) for therapy of community-acquired respiratory tract and other infections. Previous studies have highlighted the broad spectrum of activity of this compound (also known as SUN/SY 5555, ALP-201 and WY-49605) against Gram-negative, Gram-positive and also anaerobic bacteria. In addition, faropenem MICs have been shown to be unaffected by ß-lactamase production in common respiratory tract and other pathogens.1–4

In this study, broth microdilution and time–kill methodology were used to examine the in vitro activity . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
J. P Gettig, C. W Crank, and A. H Philbrick
Faropenem Medoxomil
Ann. Pharmacother., January 1, 2008; 42(1): 80 - 90.
[Abstract] [Full Text] [PDF]